Stromal CD10 Expression in Breast Carcinoma and its Association with ER, PR, and HER2/neu Using Immunohistochemistry: A Cross-sectional Study
Introduction: Breast cancer is a common and deadly malignancy affecting women worldwide. Various immune markers, such as Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal growth factor Receptor 2 (HER2/neu), are commonly used to assess prognosis. Currently, ongoing research...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2023-12-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://www.jcdr.net/articles/PDF/18869/67694_CE[Ra1]_F[SK]_QC&REF(AN_IS)_PF1(AG_DK)_PFA(KM)_PB(AG_OM)_PN(OM).pdf |
| Summary: | Introduction: Breast cancer is a common and deadly malignancy
affecting women worldwide. Various immune markers, such as
Estrogen Receptor (ER), Progesterone Receptor (PR), and Human
Epidermal growth factor Receptor 2 (HER2/neu), are commonly
used to assess prognosis. Currently, ongoing research aims to
evaluate molecular pathways that contribute to invasion and
metastasis. One important immunomarker under investigation
is CD10, a zinc-dependent Matrix Metalloproteinase (MMP) that
degrades bioactive peptides. CD10 expression in the tumour
stroma has been associated with the biological aggressiveness
of several epithelial malignancies, including breast carcinoma.
Aim: To analyse the association between stromal CD10
expression and different prognostic factors, such as age,
histological grade, and status of ER, PR, and HER2/neu markers,
in patients with breast cancer.
Materials and Methods: This institutional-based, crosssectional study was conducted at the Department of Pathology,
Nil Ratan Sircar Medical College and Hospital (NRSMC) in
Kolkata, West Bengal, India over a period of one and a half years
(February 2021 to July 2022). It included 120 cases of breast
carcinoma diagnosed through histopathological examination of
formalin fixed paraffin embedded sections, which were prepared
from trucut biopsies and resection specimens referred from the
Department of General Surgery, NRSMC. CD10 expression
was assessed by Immunohistochemistry (IHC) in all cases
and scored as negative, weak, or strong. The study examined
the association between CD10 expression and the following
parameters: age, histopathological grade, and the status of ER,
PR, and HER2/neu markers. Data were entered into Microsoft
Excel (MS) for statistical analysis. The significance of the study
was determined using the Chi-square test, and data were
analysed using Statistical Package for the Social Sciences
(SPSS) version 23.0 (IBM, Illinois, US). A p-value of <0.05 was
considered statistically significant.
Results: The study included a total of 120 cases, with 119
cases of female breast cancer (99.16%) and one case of male
breast cancer (0.84%). The mean±SD age of the patients was
54±5.038 years (range 44 to 67 years). The majority of cases 102
(85.00%) were diagnosed as Invasive Ductal Carcinoma (IDC),
Not Otherwise Specified (NOS), followed by IDC-special types
18 (15.00%). CD10 expression was evaluated in all cases, and
stromal CD10 positivity was observed in 79 out of 120 cases
(65.80%), with 39 individuals (49.40%) showing weak positivity
and 40 cases (50.60%) showing strong positivity. The remaining
41 cases (34.16%) were CD10 negative. Grade 3 cancers
were predominant in this study 62 (51.66%). It was noted that
CD10 stromal positivity increased with higher grade. Most of
the cancers in this study were negative for ER, PR, and HER2/
Neu (78, 65.00%; 84, 70.00%; and 67, 55.83%, respectively).
Stromal CD10 expression showed a significant association with
ER (p-value=0.00001), HER2/neu (p-value=0.000089), tumour
grade (p-value=0.0012), and an insignificant association with
age (p-value0.264) and PR (p-value=0.256).
Conclusion: Therefore, CD10 expression is strongly associated
with well-established prognostic markers, namely higher tumour
grade, HER2/neu negativity, and ER negativity. This indicates
that CD10 can not only be used as an independent marker of
poor prognosis but also as a target for the development of novel
therapies. |
|---|---|
| ISSN: | 2249-782X 0973-709X |